{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:08:03Z","timestamp":1791194883494,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9,10]]},"DOI":"10.1097\/qad.0b013e32833ce57d","type":"journal-article","created":{"date-parts":[[2010,7,12]],"date-time":"2010-07-12T10:34:42Z","timestamp":1278930882000},"page":"2193-2200","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacokinetics and virologic response of zidovudine\/lopinavir\/ritonavir initiated during the third trimester of pregnancy"],"prefix":"10.1097","volume":"24","author":[{"given":"Tim R","family":"Cressey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzague","family":"Jourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boonsong","family":"Rawangban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supang","family":"Varadisai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucha","family":"Kongpanichkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapan","family":"Sabsanong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapap","family":"Yuthavisuthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnuk","family":"Chirayus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ngo-Giang-Huong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipunporn","family":"Voramongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somsak","family":"Pattarakulwanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lallemant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-7-20210130","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1097\/01.aids.0000247114.43714.90","article-title":"Reduced lopinavir exposure during pregnancy","volume":"20","author":"Stek","year":"2006","journal-title":"AIDS"},{"key":"R3-7-20210130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/QAI.0b013e318186edd0","article-title":"Lopinavir exposure with an increased dose during pregnancy","volume":"49","author":"Mirochnick","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-7-20210130","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/QAD.0b013e3281053a1e","article-title":"Steady-state lopinavir levels in third trimester of pregnancy","volume":"21","author":"Lyons","year":"2007","journal-title":"AIDS"},{"key":"R6-7-20210130","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/QAD.0b013e328031f42e","article-title":"Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine","volume":"21","author":"Manavi","year":"2007","journal-title":"AIDS"},{"key":"R7-7-20210130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAD.0b013e3282f3f16d","article-title":"Lopinavir\/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients","volume":"22","author":"Delfraissy","year":"2008","journal-title":"AIDS"},{"key":"R9-7-20210130","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200101050-00002","article-title":"ABT-378\/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results","volume":"15","author":"Murphy","year":"2001","journal-title":"AIDS"},{"key":"R10-7-20210130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00007691-200306000-00023","article-title":"Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography","volume":"25","author":"Droste","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R11-7-20210130","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.ftd.0000211817.58052.b8","article-title":"Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004 \u2013 a requirement for therapeutic drug monitoring","volume":"28","author":"Holland","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R14-7-20210130","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/01.inf.0000180578.38584.da","article-title":"Pharmacokinetics and 24-week efficacy\/safety of dual boosted saquinavir\/lopinavir\/ritonavir in nucleoside-pretreated children","volume":"24","author":"Ananworanich","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R16-7-20210130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/01.ftd.0000245681.12092.d6","article-title":"A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults","volume":"28","author":"van der Leur","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R18-7-20210130","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3851\/IMP1414","article-title":"A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients","volume":"14","author":"Bouillon-Pichault","year":"2009","journal-title":"Antivir Ther"},{"key":"R19-7-20210130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1468-1293.2009.00767.x","article-title":"Lopinavir protein binding in HIV-1-infected pregnant women.","volume":"11","author":"Aweeka","year":"2010","journal-title":"HIV Med"},{"key":"R20-7-20210130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/14622416.8.3.227","article-title":"Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV","volume":"8","author":"Ma","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R21-7-20210130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/FPC.0b013e328335b02d","article-title":"HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms","volume":"20","author":"Hartkoorn","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"R22-7-20210130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FPC.0b013e328336eee4","article-title":"ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir","volume":"20","author":"Lubomirov","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"R23-7-20210130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/QAI.0b013e31803133c5","article-title":"The tablet formulation of lopinavir\/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect","volume":"44","author":"Klein","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R24-7-20210130","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1086\/514750","article-title":"Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine","volume":"28","author":"Bessesen","year":"1999","journal-title":"Clin Infect Dis"},{"key":"R25-7-20210130","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/gut.51.4.597","article-title":"Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B","volume":"51","author":"Lim","year":"2002","journal-title":"Gut"},{"key":"R26-7-20210130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/QAD.0b013e3282f3d63c","article-title":"Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort","volume":"22","author":"Warszawski","year":"2008","journal-title":"AIDS"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e32833ce57d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T07:31:35Z","timestamp":1635665495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201009100-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,10]]},"references-count":19,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32833ce57d","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9,10]]}}}